Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. Jardim DL, et al. Oncotarget. 2014 Apr 15;5(7):1837-45. doi: 10.18632/oncotarget.1828. Oncotarget. 2014. PMID: 24742823 Free PMC article. Clinical Trial.
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. de Melo Gagliato D, et al. Among authors: jardim dl. Clin Breast Cancer. 2014 Dec;14(6):468-74. doi: 10.1016/j.clbc.2014.06.001. Epub 2014 Jun 23. Clin Breast Cancer. 2014. PMID: 25065564 Free PMC article. Clinical Trial.
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.
Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. Tang C, et al. Among authors: jardim dl. Oncoscience. 2013 Dec 11;1(1):5-13. doi: 10.18632/oncoscience.3. eCollection 2014. Oncoscience. 2013. PMID: 25593979 Free PMC article.
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.
Soares A, Monteiro FSM, da Trindade KM, Silva AGE, Cardoso APG, Sasse AD, Fay AP, Carneiro APCD, Alencar Junior AM, de Andrade Mota AC, Santucci B, da Motta Girardi D, Herchenhorn D, Araújo DV, Jardim DL, Bastos DA, Rosa DR, Schutz FA, Kater FR, da Silva Marinho F, Maluf FC, de Oliveira FNG, Vidigal F, Morbeck IAP, Rinck Júnior JA, Costa LAGA, Maia MCDF, Zereu M, Freitas MRP, Dias MSF, Tariki MS, Muniz P, Beato PMM, Lages PSM, Velho PI, de Carvalho RS, Mariano RC, de Araújo Cavallero SR, Oliveira TM, Souza VC, Smaletz O, de Cássio Zequi S. Soares A, et al. Among authors: jardim dl. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):183. doi: 10.1007/s00432-024-05663-z. J Cancer Res Clin Oncol. 2024. PMID: 38594593 Free PMC article. Review.
The bladder microbiota is not significantly altered by intravesical BCG therapy.
Heidrich V, Mariotti ACH, Inoue LT, Coser EM, Dos Santos EX, Dos Santos HDB, Asprino PF, Bettoni F, Costa GAP, Bastos DA, Jardim DL, Arap MA, Camargo AA. Heidrich V, et al. Among authors: jardim dl. Urol Oncol. 2024 Jan;42(1):22.e13-22.e21. doi: 10.1016/j.urolonc.2023.11.003. Epub 2023 Nov 28. Urol Oncol. 2024. PMID: 38030469
The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis.
Lopes CDH, Antonacio FF, Moraes PMG, Asprino PF, Galante PAF, Jardim DL, de Macedo MP, Sandoval RL, Katz A, de Castro G Jr, Achatz MI. Lopes CDH, et al. Among authors: jardim dl. Int J Mol Sci. 2023 Oct 10;24(20):15035. doi: 10.3390/ijms242015035. Int J Mol Sci. 2023. PMID: 37894716 Free PMC article.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Clinical Trial.
Low-energy amplitude-modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma.
Capareli F, Costa F, Tuszynski JA, Sousa MC, Setogute YC, Lima PD, Carvalho L, Santos E, Gumz BP, Sabbaga J, de Castria TB, Jardim DL, Freitas D, Horvat N, Bezerra ROF, Testagrossa L, Costa T, Zanesco T, Iemma AF, Abou-Alfa GK. Capareli F, et al. Among authors: jardim dl. Cancer Med. 2023 Jun;12(11):12402-12412. doi: 10.1002/cam4.5944. Epub 2023 May 15. Cancer Med. 2023. PMID: 37184216 Free PMC article. Clinical Trial.
60 results